A review of trials evaluating nonstatin lipid-lowering therapies
- 42 Downloads
Recently reported clinical trials raise doubts on the effectiveness of nonstatin lipid-lowering therapies in reducing the residual risk of cardiovascular events after statin monotherapy. Addition of torcetrapib to statin therapy increased overall mortality in coronary patients despite a marked increase in high-density lipoprotein cholesterol. Combining ezetimibe with statin therapy neither further reduces carotid atherosclerosis nor slows aortic stenosis, and it has not been shown to be superior to statin monotherapy in reducing cardiovascular events. Clinical trials currently in progress will more clearly delineate the cardiovascular effects of adding either ezetimibe or extended-release niacin/laropiprant to statin therapy.
Unable to display preview. Download preview PDF.
References and Recommended Reading
- 7.Merck, Inc.: ACHIEVE Imaging Study Discontinued. Available at: http://www.merck.com/newsroom/press_releases/research_and_development/2008_0521. Accessed on August 4, 2008.
- 8.Merck, Inc.: Merck Receives Not Approvable Letter from FDA for MK-0524A (ER niacin/laropiprant). Available at: http://www.merck.com/newsroom/press_releases/research_and_development/2008_0428.html. Accessed on August 4, 2008.
- 9.Rossebo AB, Pedersen TR, Boman K, et al.: Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis. N Engl J Med 2008 (in press).Google Scholar
- 10.MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002, 360:7–22.Google Scholar
- 11.Peto R, Emberson J, Landray M, et al.: Analyses of cancer data from three ezetimibe trials. N Engl J Med 2008 (in press).Google Scholar